Lower risk for MCI and dementia also seen with moderate, high cardiovascular health in those with high polygenic risk score.

Study reveals 5.05 percent of individuals carry pathogenic/likely pathogenic variants in in large, unselected U.S. population.

Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan (Welireg) for the treatment of renal cell carcinoma.

Belimumab is linked to a reduced risk for all-cause mortality compared with azathioprine, methotrexate, and mycophenolate among patients with nonrenal SLE.

Akebia Therapeutics has decided not to initiate a clinical trial assessing vadadustat in patients with late-stage CKD not on dialysis.